.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Accenture
Medtronic
Chinese Patent Office
Queensland Health
Moodys
Deloitte
Harvard Business School
Teva
Express Scripts

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,753,677

« Back to Dashboard

Which drugs does patent 5,753,677 protect, and when does it expire?


Patent 5,753,677 protects SAMSCA and is included in one NDA. There has been one Paragraph IV challenge on Samsca.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 5,753,677

Title: Benzoheterocyclic compounds
Abstract:Novel benzoheterocyclic compounds of the formula: ##STR1## which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.
Inventor(s): Ogawa; Hidenori (Tokushima-ken, JP), Miyamoto; Hisashi (Kyoto-fu, JP), Kondo; Kazumi (Tokushima-ken, JP), Yamashita; Hiroshi (Tokushima-ken, JP), Nakaya; Kenji (Tokushima-ken, JP), Komatsu; Hajime (Tokushima-ken, JP), Tanaka; Michinori (Tokushima-ken, JP), Kora; Shinya (Nagasaki-ken, JP), Tominaga; Michiaki (Tokushima-ken, JP), Yabuuchi; Yoichi (Tokushima-ken, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/474,544
Patent Claim Types:
see list of patent claims
Use; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka America PharmSAMSCAtolvaptanTABLET;ORAL022275-001May 19, 2009RXYesNo► Subscribe► SubscribeMETHOD OF TREATING HYPONATREMIA► Subscribe
Otsuka America PharmSAMSCAtolvaptanTABLET;ORAL022275-002May 19, 2009RXYesYes► Subscribe► SubscribeMETHOD OF TREATING HYPONATREMIA► Subscribe
Otsuka America PharmSAMSCAtolvaptanTABLET;ORAL022275-003May 19, 2009DISCNYesNo► Subscribe► SubscribeMETHOD OF TREATING HYPONATREMIA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,753,677

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,258,510 United States Patent: 5258510   ( 1► Subscribe
5,985,869 Benzoheterocyclic compounds► Subscribe
5,559,230 Benzoheterocyclic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,753,677

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil1100245► Subscribe
China1027505► Subscribe
China1107146► Subscribe
China1048484► Subscribe
Germany69026708► Subscribe
Germany122009000062► Subscribe
Denmark0450097► Subscribe
European Patent Office0450097► SubscribeCA 2009 00031Denmark► Subscribe
European Patent Office0450097► SubscribeSPC/GB09/037United Kingdom► Subscribe
European Patent Office0450097► Subscribe300408Netherlands► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Citi
Express Scripts
Cerilliant
Medtronic
US Department of Justice
Argus Health
Moodys
Cipla
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot